Dr. George Somlo on Advances in Multiple Myeloma

Video

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

Several new agents have been approved by the FDA in the past year, and oncologists are quickly learning how to best use them, says Somlo.

More and more patients are experiencing complete remissions, or at the least, very good partial remissions that eliminate 90% of the mutational load. Many of those patients can then receive an autologous stem cell transplant and the receive maintenance therapy, accomplishing minimal residual disease.

This directly translates into longer survival and a dramatically improved quality of life, says Somlo.

Oncologists that treat patients with multiple myeloma need to be aggressive, use the latest tools and agents, and enroll patients in clinical trials when applicable, says Somlo.

Related Videos
Saad Z. Usmani, MD, MBA, FACP, FASCO
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Francesco Di Meo, PhD
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Samer A. Srour, MB ChB, MS
Rebecca L. Porter, MD, PhD